title: Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for rethinking treatment strategies?
authors.affiliation: Fond IRCCS Istituto Tumori Milano , Head and Neck Medical Oncology Unit, Milan, Italy .
authors.forename: Lisa
authors.initials: L
authors.lastname: Licitra
authors.forename: Laura
authors.initials: L
authors.lastname: Locati
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D004937:Esophageal Fistula / Q000139:chemically induced*; D006801:Humans; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D016156:Respiratory Tract Fistula / Q000139:chemically induced*; D013964:Thyroid Neoplasms / Q000188:drug therapy*; D014138:Tracheoesophageal Fistula / Q000139:chemically induced*
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D020794:Receptor Protein-Tyrosine Kinases